- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04973163
En studie for å teste forskjellige doser av BI 1823911 alene og kombinert med andre medisiner hos personer med forskjellige typer avansert kreft med KRAS-mutasjon
En fase Ia/Ib, åpen, multisenter doseeskalerings- og utvidelsesstudie for å undersøke sikkerheten, farmakokinetikken og den foreløpige effekten av BI 1823911 som monoterapi og i kombinasjon med andre anti-kreftterapier hos pasienter med avanserte eller metastatiske faste svulster. KRAS G12C mutasjon
This study is open to adults with different types of advanced or metastatic cancer (including lung cancer, colorectal cancer, pancreatic cancer, and bile duct cancer). This study is for people for whom previous treatment was not successful or no treatment exists.
People who have a tumour with a KRAS mutation can participate in the study. A KRAS mutation makes tumours grow faster. BI 1823911 and BI 1701963 are medicines that may turn off KRAS, each in a different way. In this study, BI 1823911 is given to people for the first time.
The purpose of this study is to find the highest dose of BI 1823911 that people can tolerate when taken alone and together with BI 1701963. The most suitable dose is used to find out whether BI 1823911 alone and in combination with BI 1701963 can make tumours shrink.
Participants can stay in the study as long as they benefit from treatment and can tolerate it.
During this time, participants take tablets of BI 1823911 alone or in combination with BI 1701963 once a day. The doctors regularly monitor the size of the tumour. Doctors also regularly record any unwanted effects and check participant's health.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Anderlecht/Brussels-Capital, Belgia, 1070
- Brussels - HOSP Jules Bordet
-
Edegem/Antwerpen, Belgia, 2650
- Universitair Ziekenhuis Antwerpen
-
Gent/Oost-Vlaanderen, Belgia, 9000
- Universitair Ziekenhuis Gent
-
Leuven/Vlaams-Brabant, Belgia, 3000
- UZ Leuven
-
-
-
-
New York
-
New York, New York, Forente stater, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Texas
-
Dallas, Texas, Forente stater, 75230
- Sarah Cannon Research Institute at Mary Crowley
-
Houston, Texas, Forente stater, 77030
- The University of Texas MD Anderson Cancer Center
-
-
-
-
-
Barcelona, Spania, 08035
- Hospital Universitari Vall d'Hebron
-
-
-
-
-
Manchester, Storbritannia, M20 4BX
- The Christie
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Pathologically confirmed diagnosis of locally advanced or metastatic solid tumours, e.g. adenocarcinoma of the lung, colorectal cancer, pancreatic cancer or cholangiocarcinoma. Non-small cell lung cancer (NSCLC) patients with mixed histology are eligible if adenocarcinoma is the predominant histology.
-
Documented disease progression despite appropriate prior standard therapies or for whom no standard therapy exists for their tumour type and disease stage.
-
KRAS mutation status: Kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation in tumour tissue or blood based on previously performed local testing using a validated test.
-
Provision of archival tumour tissue, if available, to confirm retrospectively KRAS G12C mutation status and for biomarker assessment.
-
At least one target lesion that can be measured per Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (radiated lesions do not qualify as target lesions). In patients who only have one target lesion, and a biopsy of the lesion is required, the baseline imaging must be performed before the biopsy or at the earliest two weeks after the biopsy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Adequate organ function as follows:
- Absolute neutrophil count (ANC) ≥1.5 x 10^9/L (equivalent values: ≥ 1.5 x 10³/μL or ≥ 1500/mm³); hemoglobin ≥9.0 g/dL (equivalent values: ≥ 90 g/L or ≥ 5.6 mmol/L); platelets ≥100 x 10^9/L (equivalent values: ≥ 100 x 10³/μL or ≥ 100 x 10³/mm³) without the use of haematopoietic growth factors.
- Total bilirubin ≤1.5 times the upper limit of normal (ULN), or ≤4 x ULN for patients who are known to have Gilbert's syndrome.
- Creatinine ≤1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if concurrent creatinine clearance ≥50 mL/min (equivalent value: 0.84mL/s) (measured or calculated by Cockcroft-Gault formula).
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN, for patients with liver metastases ≤5 x ULN.
-
Age ≥18 years of age, or over the legal age of consent as required by local legislation.
Further inclusion criteria apply.
Exclusion Criteria:
- Previous anticancer chemotherapy within 3 weeks of the first administration of trial drug. Previous anticancer hormonal treatment or anticancer immunotherapy within 2 weeks of the first administration of trial drug.
- Previous treatment with Rat Sarcoma (RAS), Mitogen-activated protein kinase (MAPK) or Son of sevenless 1 (SOS1) targeting agents (only for monotherapy Parts A, B, and C).
- Radiotherapy within 2 weeks prior to start of treatment, provided recovery from related toxicity.
- Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of treatment or planned during the projected course of the trial, e.g. hip replacement.
- Previous treatment with any investigational agent(s) or targeted treatment within 28 days prior to start of treatment or 5 half-lives, whichever is shorter.
- Known history of hypersensitivity to any of the excipients of BI 1823911 tablets, or any contraindication to Midazolam (for Monotherapy Part B only).
- History or presence of cardiovascular abnormalities such as congestive heart failure New York Heart Association (NYHA) classification of ≥3, unstable angina or poorly controlled arrhythmia which are considered clinically relevant by the Investigator. Myocardial infarction within 6 months prior to start of treatment. Uncontrolled hypertension defined as: Blood pressure (BP) measured in a rested and relaxed condition, where systolic BP >=140 mmHg, or diastolic BP >= 90 mmHg, with or without medication.
- Left ventricular ejection fraction (LVEF) <50%. Further exclusion criteria apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Monotherapy Arm
Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C). |
BI 1823911 Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm |
|
Eksperimentell: Combination Therapy Arm
Will be started after confirmation of safety in the Monotherapy Arm. Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C). |
BI 1823911 BI 1701963 |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Dose escalation (Part A) - Monotherapy and combination therapy: Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period for BI 1823911 in monotherapy and in each combination
Tidsramme: up to 28 days
|
DLTs are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
up to 28 days
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR) defined as best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR)
Tidsramme: up to 39 months
|
BOR is determined according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. |
up to 39 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Doseeskalering (del A) - Monoterapi og kombinasjonsterapi: Antall pasienter som opplever DLT under alle behandlingssykluser for BI 1823911 i monoterapi og i hver kombinasjon
Tidsramme: opptil 39 måneder
|
opptil 39 måneder
|
|
|
Alle studiedeler: Antall pasienter med uønskede hendelser i løpet av behandlingsperioden
Tidsramme: opptil 39 måneder
|
opptil 39 måneder
|
|
|
Alle studiedeler, BI 1823911: Maksimal konsentrasjon (Cmax)
Tidsramme: opptil 24 timer
|
opptil 24 timer
|
|
|
Alle studiedeler, BI 1823911: Steady state-konsentrasjon (Css)
Tidsramme: opptil 24 timer
|
opptil 24 timer
|
|
|
Alle studiedeler, BI 1823911: Areal under plasmakonsentrasjon-tid-kurven fra tid null til tid t (AUCτ)
Tidsramme: opptil 24 timer
|
opptil 24 timer
|
|
|
Alle studiedeler, BI 1823911: Areal under plasmakonsentrasjon-tid-kurven ved steady state (AUCss)
Tidsramme: opptil 24 timer
|
opptil 24 timer
|
|
|
Alle studiedeler, BI 1701963: Maksimal konsentrasjon (Cmax)
Tidsramme: opptil 24 timer
|
opptil 24 timer
|
|
|
Alle studiedeler, BI 1701963: Steady state-konsentrasjon (Css)
Tidsramme: opptil 24 timer
|
opptil 24 timer
|
|
|
Alle studiedeler, BI 1701963: Areal under plasmakonsentrasjon-tid-kurven fra tid null til tid t (AUCτ)
Tidsramme: opptil 24 timer
|
opptil 24 timer
|
|
|
Alle studiedeler, BI 1701963: Areal under plasmakonsentrasjon-tid-kurven ved steady state (AUCss)
Tidsramme: opptil 24 timer
|
opptil 24 timer
|
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR)
Tidsramme: up to 39 months
|
OR is defined as best overall response (BOR) of complete response (CR) or partial response (PR), both regardless of confirmation. BOR is determined according to RECIST version 1.1. BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Duration of OR
Tidsramme: up to 39 months
|
Duration of OR is defined as the time from first documented CR or PR until disease progression or death (whichever occurs first) among patients with OR. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Tumour shrinkage (in millimetres)
Tidsramme: up to 39 months
|
Tumour shrinkage is defined as the difference between the minimum post-baseline sum of diameters of target lesions (longest for non-nodal lesions, short axis for nodal lesions) and the baseline sum of longest diameters of the same set of target lesions. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Progression-free survival (PFS) rate
Tidsramme: at month 6
|
PFS is defined as the time from first treatment administration until tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs earlier. |
at month 6
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 1472-0001
- 2021-000460-29 (EudraCT-nummer)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).
For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .